- "The warning on the drug's label is one of the strongest issued by the regulator," Reuters says, referring to the FDA's mention of an increase in the risk of asthma-related death with GlaxoSmithKline (GSK +0.2%) and Theravance's (THRX -1.5%) Anoro Ellipta.
- The risk stems from vilanterol, the drug's LABA component.
- The COPD treatment won FDA approval on Wednesday.
- Analysts see annual sales hitting ~$2.65B by 2018, Reuters notes.
- FDA release
New Glaxo, Theravance COPD drug carries strong warning
Dec 19 2013, 11:26 ET